Ixekizumab: all 54 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy ParticipantsRecruitingNCT07789964Phase 1
• Combination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisRecruitingNCT07443956Not applicable
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Ixekizumab Versus Secukizumab in Over 70-year-old Patients with PsoriasisNot yet recruitingNCT06811558Not applicable
• Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingNCT06398106Phase 4
• Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate PsoriasisNot yet recruitingNCT06374979Phase 2/3
• Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNCT05503875Not applicable
• Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
• Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque PsoriasisRecruitingNCT04537689Phase 4
• A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in IndiaCompletedNCT05855967Phase 4Results posted
• Targeting IL-17A for Treatment-Resistant DepressionCompletedNCT04979910Phase 2Results posted
• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisActive, not recruitingNCT04527380Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial SpondyloarthritisCompletedNCT04285229Phase 3Results posted
• A Study of Two Formulations of Ixekizumab in Healthy ParticipantsCompletedNCT04259346Phase 1Results posted
• A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic PsoriasisCompletedNCT03942042Phase 4Results posted
• A Study of Ixekizumab in Healthy ParticipantsCompletedNCT03848416Phase 1Results posted
• Study of Ixekizumab in Healthy ParticipantsTerminatedNCT03848403Phase 1Results posted
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03573323Phase 4Results posted
• Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)CompletedNCT03485976Phase 2Results posted
• A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03364309Phase 3Results posted
• A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic ArthritisCompletedNCT03151551Phase 4Results posted
• An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumCompletedNCT03137160Phase 2Results posted
• A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial SpondyloarthritisCompletedNCT03129100Phase 3Results posted
• Ixekizumab in the Treatment of Bullous PemphigoidCompletedNCT03099538Phase 2Results posted
• A Study of Ixekizumab in Chinese Participants With Psoriasis VulgarisCompletedNCT03073213Phase 1Results posted
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque PsoriasisCompletedNCT03073200Phase 3Results posted
• A Study of Ixekizumab in Participants With Plaque PsoriasisCompletedNCT02993471Phase 1Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial SpondyloarthritisCompletedNCT02757352Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital PsoriasisCompletedNCT02718898Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial SpondyloarthritisCompletedNCT02696798Phase 3Results posted
• A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic ArthritisCompletedNCT02584855Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT02561806Phase 3Results posted
• A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy ParticipantsCompletedNCT02543918Phase 1Results posted
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02513550Phase 3Results posted
• A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe PsoriasisCompletedNCT02387801Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic ArthritisCompletedNCT02349295Phase 3Results posted
• Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT01777191Phase 3Results posted
• A Study of Ixekizumab in Participants With Active Psoriatic ArthritisCompletedNCT01695239Phase 3Results posted
• A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)CompletedNCT01646177Phase 3Results posted
• A Study in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT01624233Phase 3Results posted
• A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)CompletedNCT01597245Phase 3Results posted
• A Phase 3 Study in Participants With Moderate to Severe PsoriasisCompletedNCT01474512Phase 3Results posted
• A Study in Rheumatoid ArthritisCompletedNCT01253265Phase 1Results posted
• A Study of LY2439821 in Rheumatoid ArthritisCompletedNCT01236118Phase 1Results posted
• A Study in Participants With Moderate to Severe PsoriasisCompletedNCT01107457Phase 2Results posted
• A Study in Patients With Rheumatoid ArthritisCompletedNCT00966875Phase 2Results posted
• Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy SubjectsActive, not recruitingNCT07200986Phase 1
• Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic StenosisCompletedNCT05309616Phase 2
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)CompletedNCT04724629Phase 3
• Ixekizumab Diabetes Intervention Trial (I-DIT)Active, not recruitingNCT04589325Phase 2
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)WithdrawnNCT01870284Phase 3

← Ixekizumab overview